Inventor · disambiguated record
Tahamtan Ahmadi
Also filed as: AHMADI TAHAMTAN
8 granted patents·23 pending applications·56 citations·filing 2016–2024
86Inventor score
Top patents by PatentIndex Score
31 records- 0196US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 0296US11535679B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Dec 27, 2022·8 cites·27 claims
- 0395US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 0495US11548952B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Jan 10, 2023·7 cites·27 claims
- 0593US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 0692US11021543B2Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38JANSSEN BIOTECH INC·Filed 2018·Granted Jun 1, 2021·13 cites·19 claims
- 0791US11618787B2Methods of treating high risk multiple myelomaJANSSEN BIOTECH INC·Filed 2018·Granted Apr 4, 2023·10 cites·12 claims
- 0880US2025066501A1Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38JANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 0978US12435154B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2021·Granted Oct 7, 2025·1 cites·29 claims
- 1078US2024301078A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 1177US2024317881A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2024·Application pending·0 cites
- 1269US2021403592A1Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38JANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 1368US2023340145A1Methods of Treating High Risk Multiple MyelomaJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1468US2024034812A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1565US2022112309A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1664US2023355753A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1763US2023312758A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1863US2023357440A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1961US2023312757A1Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Application pending·0 cites
- 2061US2020017600A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2019·Application pending·0 cites
- 2160US2020165352A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2020·Application pending·0 cites
- 2257US2025382378A1Cd38 antibodies and uses thereofGENMAB AS·Filed 2023·Application pending·0 cites
- 2357US2023312759A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 2456US2024109972A1Antibody and taxane combination therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 2555US2017044265A1Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38JANSSEN BIOTECH INC·Filed 2016·Application pending·0 cites
- 2650US2021393793A1Axl-specific antibodies for treatment of non-small cell lung cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 2748US2022315661A1Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancerGENMAB BV·Filed 2020·Application pending·0 cites
- 2847US2021070869A1Axl-specific antibodies for cancer treatmentGENMAB AS·Filed 2019·Application pending·0 cites
- 2947US2022273809A1Axl antibody-drug conjugates for use in treating cancerGENMAB AS·Filed 2020·Application pending·0 cites
- 3046US2024254252A1Trogocytosis-mediated therapy using cd38 antibodiesGENMAB AS·Filed 2019·Application pending·0 cites
- 3139US2016376373A1Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38JANSSEN BIOTECH INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →